Entremed (ENMD)

[Rocky I]

Data Presented For ENMD-2076 In Xenograft Models Of Human Hepatocellular Carcinoma




ROCKVILLE, Md., Oct. 22, 2013 - EntreMed, Inc. (ENMD), a
clinical-stage pharmaceutical company developing therapeutics for the
treatment of a variety of cancers, announced today the presentation of
preclinical data for a study comparing the efficacy of ENMD-2076
against that of standard of care agents including sorafenib,
doxorubicin, and 5-FU for human hepatocellular carcinoma (HCC)
models. The results of the study were presented at AACR-NCI EORTC
International Conference being held this week in Boston,
Massachusetts.

The data presented demonstrate significant in vivo activity of
ENMD-2076 against three different human hepatocellular carcinoma
xenograft models and concluded that ENMD-2076 showed robust antitumor
activity against the cell line-derived xenograft models of human HCC
superior to that of sorafenib, doxorubicin, and 5-FU.

Ken K. Ren, Ph.D., EntreMed's Chief Executive Officer, commented,
"HCC represents the third leading cause of cancer deaths worldwide.
There are unmet medical needs for drugs with better safety and
efficacy. This in vivo preclinical study data is affirmative with
our previous in vitrofindings that greater than 60% of 21 liver
cancer-derived cell lines we screened are significantly inhibited by
ENMD-2076 treatment. It also indicates that ENMD-2076 may be
effective in patients resistant to sorafenib or 5-FU. In our Phase 1
trial of ENMD-2076, partial response with prolonged progression free
survival was observed in a patient with liver cancer who relapsed from
standard care including liver transplantation and sorafenib treatment.
This preclinical study provides support for further clinical
investigation of the drug candidate in HCC patients who do not
tolerate, or have failed or relapsed from other systemic treatment,
particularly sorafenib or 5-FU. We believe that ENMD-2076 has
potential in the HCC market, especially in China, where more than 50%
of global incidence occurs."

To view the poster presentation, visit the Company's website at
http://www.entremed.com.

About ENMD-2076
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor
with a unique kinase selectivity profile and multiple mechanisms of
action. ENMD-2076 has been shown to inhibit a distinct profile of
angiogenic tyrosine kinase targets in addition to the Aurora A
kinase. Aurora kinases are key regulators of mitosis (cell
division), and are often over-expressed in human cancers. ENMD-2076
also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown
to play important roles in the pathology of several cancers.
ENMD-2076 has shown promising activity in Phase 1 clinical trials in
solid tumor cancers, leukemia, multiple myeloma, and is currently
completing a Phase 2 trial for ovarian cancer. EntreMed is currently
conducting a Phase 2 study of ENMD-2076 in triple-negative breast
cancer, a Phase 2 study in advanced/metastatic soft tissue sarcoma,
and expecting to initiate a Phase 2 study in ovarian clear cell
carcinoma. ENMD-2076 has received orphan drug designation from the
FDA for the treatment of ovarian cancer, multiple myeloma and acute
myeloid leukemia.

About EntreMed
EntreMed is a clinical-stage pharmaceutical company employing a drug
development strategy primarily in the United States and China to
develop targeted therapeutics for the global market. Its lead
compound, ENMD-2076, a selective angiogenic kinase inhibitor, has
completed several Phase 1 studies in solid tumors, multiple myeloma,
and leukemia, and is currently completing a multi-center Phase 2 study
in ovarian cancer. EntreMed is currently conducting a Phase 2 study
of ENMD-2076 in triple-negative breast cancer, a Phase 2 study of
ENMD-2076 in advanced/metastatic soft tissue sarcoma, and is expecting
to initiate a Phase 2 study in ovarian clear cell carcinoma. The
Company is headquartered in Rockville, Maryland and has a wholly-owned
subsidiary in Beijing, China. Additional information about EntreMed
is available on the Company's web site atwww.entremed.com and in
various filings with the Securities and Exchange Commission (the SEC).


Forward Looking Statements
This release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act with respect to the
outlook for expectations for future financial or business performance,
strategies, expectations and goals. Forward-looking statements are
subject to numerous assumptions, risks and uncertainties, which change
over time. Forward-looking statements speak only as of the date they
are made, and no duty to update forward-looking statements is assumed.


Actual results could differ materially from those currently
anticipated due to a number of factors, including: the risk that we
may be unable to continue as a going concern as a result of our
inability to raise sufficient capital for our operational needs; the
possibility that we may be delisted from trading on the Nasdaq Capital
Market; the volatility of our common stock; the difficulty of
executing our business strategy in China; our inability to enter into
strategic partnerships for the development, commercialization,
manufacturing and distribution of our proposed product candidate or
future candidates; risks relating to the need for additional capital
and the uncertainty of securing additional funding on favorable terms;
declines in actual sales of Thalomid® resulting in reduced or no
royalty payments; risks associated with our product candidates; any
early-stage products under development; results in preclinical models
are not necessarily indicative of clinical results; uncertainties
relating to preclinical and clinical trials, including delays to the
commencement of such trials; the lack of success in the clinical
development of any of our products; dependence on third parties; and
risks relating to the commercialization, if any, of our proposed
products (such as marketing, safety, regulatory, patent, product
liability, supply, competition and other risks). Such factors, among
others, could have a material adverse effect upon our business,
results of operations and financial condition. We caution readers
not to place undue reliance on any forward-looking statements, which
only speak as of the date made. Additional information about the
factors and risks that could affect our business, financial condition
and results of operations, are contained in our filings with the U.S.
Securities and Exchange Commission ("SEC"), which are available
atwww.sec.gov.

http://www.entremed.com/news/data-presented-for-enmd-2076-in-xenograft-models-of-human-hepatocellular-carcinoma/

________________________________________________________

You are receiving this email from EntreMed, Inc. because you requested to receive press releases electronically.
If you would like to stop receiving emails from us, please click the link below.

http://www.entremed.com/cancel/1b78f080e7a02818f5de54cd0080818b&cancel